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Identification of novel transcripts 
and peptides in developing murine 
lens
Shahid Y. Khan1, Muhammad Ali1, Firoz Kabir1, Ruiqiang Chen2, Chan Hyun Na2,  
Mei-Chong W. Lee3, Nader Pourmand3, Sean F. Hackett1 & S. Amer Riazuddin1
We previously investigated the transcriptome and proteome profiles of the murine ocular lens at six 
developmental time points including two embryonic (E15 and E18) and four postnatal time points (P0, 
P3, P6, and P9). Here, we extend our analyses to identify novel transcripts and peptides in developing  
mouse lens. We identified a total of 9,707 novel transcripts and 325 novel fusion genes in developing 
mouse lens. Additionally, we identified 13,281 novel alternative splicing (AS) events in mouse lens 
including 6,990 exon skipping (ES), 2,447 alternative 3′ splice site (A3SS), 1,900 alternative 5′ splice 
site (A5SS), 1,771 mutually exclusive exons (MXE), and 173 intron retention (IR). Finally, we integrated 
our OMIC (Transcriptome and Proteome) datasets identifying 20 novel peptides in mouse lens. All 20 
peptides were validated through matching MS/MS spectra of synthetic peptides. To the best of our 
knowledge, this is the first report integrating OMIC datasets to identify novel peptides in developing 
murine lens.
Next-generation RNA sequencing (RNA-Seq) has significantly enhanced our ability to decipher whole tran-
scriptomes through the gene expression quantification, identification of novel transcripts, detection of fusion 
genes, and isoform diversity1–7. The mouse genome encodes 53,715 genes, including 21,981 protein-coding genes 
(GENCODE Ver. M17). However, the total number of transcripts encoded by these genes is believed to be much 
higher suggesting multiple layers of complexity at the transcriptome level8,9.
Fusion genes describe a phenomenon of hybrid RNA resulting from read-through transcripts, composed 
of two different genes formed during chromosomal re-arrangements10,11. Fusion genes could be a product of 
cis-splicing as well as trans-splicing12–15. Alternative mRNA splicing, a phenomenon more prevalent in higher 
eukaryotes, provides additional diversity in gene expression8,16, and according to some estimates >95% of human 
multi-exonic mRNAs undergo mRNA splicing9,17,18.
The ocular tissue especially the retina has been characterized extensively using multiple next-generation based 
transcriptome studies that revealed highly diverse annotated and novel transcriptome and novel isoforms19,20. In 
contrast, the characterization of the lens expression profile has received less attention and fewer next-generation 
RNA sequencing-based studies have been completed. Recently, Srivastava and colleagues identified novel tran-
scripts and splicing alterations in developing murine lens21.
We previously reported the mouse lens coding and non-coding transcriptome at six developmental time 
points including two embryonic (E15 and E18) and four postnatal stages (P0, P3, P6, and P9)22,23. More recently, 
we reported a comprehensive proteome of the mouse lens at the same six developmental time points24. Here, we 
extend our analyses to identify novel transcripts and peptides in developing mouse lens.
Results
Here, we extend our analysis of the RNA-Seq data using multiple bioinformatics tools to identify novel tran-
scripts, fusion genes, and alternative splicing (AS) in developing mouse lens (Fig. 1). Additionally, we integrate 
our OMIC (Transcriptome and Proteome) datasets to identify novel peptides in mouse lens and subsequently 
validated them through matching MS/MS spectra of synthetic peptides (Fig. 1).
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First, the raw reads were mapped to the Mus musculus genome resulting in >93% alignment to the genome. 
Next, the aligned reads were examined for PCR duplicates identifying ~19% of total reads as PCR duplicates that 
were removed. The remaining mapped reads were processed using StringTie to convert the RNA-Seq alignments 
into potential transcripts and the expression of each transcript was measured and normalized using transcripts 
per million (TPM) algorithm. Our analysis identified both annotated and novel transcripts in mouse lens tran-
scriptome. We divided the novel transcripts further into two categories: first, transcripts that map entirely to the 
unannotated regions of the mouse genome and second, transcripts that partially align to both annotated and 
unannotated regions of the mouse genome.
We identified a total of 21,265 annotated transcripts expressed in at least one of the six developmental time 
points (Table 1 & Supplementary Table 1). Of these, we identified 9,707 novel transcripts present in at least 
one of the six developmental stages mapping entirely to unannotated regions of the mouse genome (Table 1 & 
Supplementary Table 2). Additionally, we identified 14,113 transcripts aligned to both the annotated and the 
unannotated regions of the mouse genome (Table 1 & Supplementary Table 3) termed hereafter as semi-novel 
transcripts.
We further investigated our mRNA sequencing data to identify fusion genes expressed in the mouse lens 
transcriptome. The analysis identified 325 novel fusion genes including 195, 161, 275, 218, 280, and 223 fusion 
genes in the mouse lens at E15, E18, P0, P3, P6, and P9, respectively (Table 1 & Supplementary Table 4). Gene 
ontologies (GO) based functional and mammalian phenotype enrichment analysis of novel fusion genes revealed 
Figure 1. Illustration of the workflow to identify novel transcripts and peptides in developing mouse lens. 
Briefly, HISAT2, a splice aligner tool was used for the alignment of mouse lens RNA-Seq reads (FASTQ) to 
the mouse genome, followed by the transcripts annotation and expression quantification using the StringTie 
algorithm. In parallel, the RNA-Seq aligned data was further processed using JAFFA, and rMATS algorithms to 
detect fusion genes, and alternative splicing events, respectively, expressing in mouse lens. The novel transcripts 
(≥1.0TPM) were analyzed using a proteogenomics approach to identify novel peptides. The novel transcripts 
were translated into potential open reading frames (ORFs) to generate a reference database. The mouse lens 
proteome data (MS/MS spectra) was searched against this reference database to identify novel peptides. Finally, 
the novel peptides were validated through matching MS/MS spectra of synthetic peptides.
Developmental 
Stage
Transcripts expression (≥1.0 TPM)
Annotated Novel Semi-novel Fusion Genes
E15 18,087 6,645 11,025 195
E18 17,500 7,061 10,335 161
P0 17,257 7,569 11,194 275
P3 17,257 7,513 11,199 218
P6 16,656 7,293 10,831 280
P9 16,674 7,084 10,605 223
Total 21,265 9,707 14,113 325
Table 1. Transcripts identified in developing mouse lens. Note: E15 and E18 are embryonic days 15, and 18, and 
P0, P3, P6, and P9 are postnatal days 0, 3, 6, and 9, respectively; TPM: transcripts per million.
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(q-value ≤ 0.01) unique molecular function, biological process, cellular component and mammalian phenotypes 
(Supplementary Tables 5–6).
Next, we examined our RNA-Seq dataset using the rMATS pipeline (≤0.01 FDR) to identify the novel AS 
events across the six developmental time points in mouse lens. In total, we identified five AS events including 
exon skipping (ES), alternative 3′ splice site (A3SS), alternative 5′ splice site (A5SS), mutually exclusive exons 
(MXE), and intron retention (IR) in developing mouse lens (Table 2). The analysis identified 6,990 novel ES 
splicing events (≤0.01 FDR) across the six developmental time points in mouse lens (Supplementary Table 7). 
Of these 2,023 events present in at least one developmental time point, and 4,967 ES events in ≥2-time points 
(Supplementary Table 7).
We identified 2,447 novel A3SS splicing events (≤0.01 FDR) including 809 events detected in a single devel-
opmental time point and 1,638 events in ≥2-time points (Supplementary Table 8). Likewise, we identified 1,900 
novel A5SS splicing events including 719 events detected in a single developmental time point and 1,181 events 
in ≥2-time points (Supplementary Table 9). Furthermore, we identified 1,771 novel MXE splicing events (≤0.01 
FDR) including 387 events detected in a single developmental time point and 1,384 events in ≥2-time points 
(Supplementary Table 10). Lastly, our analysis identified 173 IR splicing events (≤0.01 FDR) in mouse lens 
(Supplementary Table 11).
Our RNA-Seq datasets are critical in identifying novel transcripts; however, the biological significance of these 
events is incomplete without knowing the corresponding changes at the protein level. We recently investigated 
the proteome profile of developing mouse lens through mass spectrometry-based protein sequencing24. We inte-
grated our OMIC datasets to identify novel peptides in mouse lens. As mentioned above, we identified a total 
of 9,707 novel transcripts that were translated into three open reading frames (ORFs) to identify all theoretical 
peptides translated by the novel transcripts. This theoretical peptide dataset was interrogated against the mouse 
lens proteome to identify peptides originating from a sequence of the novel transcripts (9,707 novel transcripts 
identified in the mouse lens transcriptome). The analysis identified 55 peptides in the mouse lens proteome based 
on TMT spectra. All of the 55 candidate peptides were screened against the mouse non-redundant (nr) protein 
database (NCBI) and peptides with ≥2 amino acids mismatches and an XCorr score ≥2.5 were considered novel. 
This criterion identified a total of 20 novel peptides that were retained for further analysis.
All 20 novel peptides along with three control peptides were synthesized commercially and the respective 
spectra of these synthetic peptides were generated using the Orbitrap Fusion Lumos Tribrid Mass Spectrometer. 
The MS/MS fragmentation patterns of synthetic peptides were manually compared with MS/MS spectra gener-
ated from the proteomic analysis of mouse lens. The control peptides revealed similar spectra consistent with the 
MS/MS fragmentation patterns originating from mouse lens proteome (Supplementary Figs 1–3). The MS/MS 
fragmentation patterns of all 20 synthetic peptides (representing 20 novel peptides) exhibited spectrum consistent 
the MS/MS fragmentation patterns originating from mouse lens proteome dataset (Table 3, Fig. 2, Supplementary 
Figs 4–20, and Supplementary Table 12).
Discussion
We previously investigated mouse lens transcriptome at two embryonic (E15 and E18) and four postnatal (P0, 
P3, P6, and P9) time points using next-generation RNA sequencing, which identified a total of 14,465 genes 
along with 12 different classes of non-coding RNAs (ncRNAs) in mouse lens22,23. More recently, we completed a 
comprehensive proteome of mouse lens at the same six developmental time points identifying 5,404 proteins24. A 
brief overview of these published datasets is provided in Table 4. In here, we extend our analyses to identify novel 
transcripts and novel peptides in developing mouse lens.
Our analysis revealed 9,707 novel transcripts identified in six developmental time points (Table 1, and 
Supplementary Table 2). Of these, ~25% are multi-exonic and ~40% are expressed in all six developmental time 
points (Supplementary Table 2). In addition to novel transcripts, we identified a total of 14,113 semi-novel tran-
scripts in lens transcriptome (Table 1, and Supplementary Table 3). In contrast to the novel transcripts where 
a majority (~75%) of the transcript are single exon, most of the semi-novel transcripts (>85%) revealed a 
multi-exonic structure i.e. ≥2.0 exons (Supplementary Tables 2 and 3).
We identified 325 novel fusion genes in developing mouse lens (Table 1). Among these, we identified multi-
ple fusion transcripts for CryαA, CryαB, CryβA1, CryβA2, CryβA4, CryβB1, CryβB2, CryβB3, CryƔA, CryƔC, 
CryƔD, CryƔE, and CryƔS (Supplementary Table 4). Additionally, we identified fusion transcripts for Bfsp1, 
Bfsp2, Tdrd7, Mip, Lim2, Pax6, and Dnase2β in mouse lens (Supplementary Table 4). Multiple studies have 
reported fusion genes in normal human and mouse tissues and more importantly, in tumorigenesis25–28. We did 
not find any reports in literature, and therefore this would be the first report describing fusion genes in the ocular 
lens.
Multiple transcriptome-based studies have revealed extensive AS in normal human and mouse ocular tis-
sues29–35. We identified 13,281 novel AS events in developing mouse lens with a predominant contribution 
from ES, A3SS, A5SS, and MXE while a small number of IR splicing events identified in developing mouse lens 
(Table 2). The ES events contribute to the diversity of the transcriptome and consistent with this notion, we identi-
fied a total of 6,990 ES events in developing mouse lens. Interestingly, most of the ES were identified at embryonic 
time points (Table 2).
Recently, Srivastava and colleagues reported the identification of 1,241 AS events in developing mouse lens21, 
examining RNA-Seq datasets recently published by our group22. We identified a total of 13,281 AS events in devel-
oping mouse lens analyzing the same RNA-Seq datasets. The difference in the numbers of AS events published 
by Srivastava and colleagues and identified in the current study may be attributed to different cut-off values. 
Srivastava and colleagues used PSI (Percent Spliced Index) cut-off value for significant (<1% FDR) AS events21, 
whereas we used a cut-off value of ≤0.01 FDR for the identification of AS events in developing mouse lens.
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Developmental Stage Types of AS Events Total AS Events Significant Novel AS Events*
E15 vs. E18
ES 22160 416
MXE 3069 93
A5SS 9753 162
A3SS 13755 306
IR 575 23
E15 vs. P0
ES 26560 521
MXE 4379 124
A5SS 10743 97
A3SS 14818 93
IR 646 11
E15 vs. P3
ES 23261 336
MXE 3881 107
A5SS 10247 106
A3SS 14215 107
IR 605 8
E15 vs. P6
ES 22898 459
MXE 3827 129
A5SS 10119 110
A3SS 14093 119
IR 617 8
E15 vs. P9
ES 21982 444
MXE 3872 121
A5SS 9859 97
A3SS 13623 94
IR 559 13
E18 vs. P0
ES 23579 1107
MXE 3470 194
A5SS 9295 259
A3SS 12849 309
IR 557 26
E18 vs. P3
ES 20212 810
MXE 3321 219
A5SS 8888 233
A3SS 12271 287
IR 515 19
E18 vs. P6
ES 19789 931
MXE 3109 198
A5SS 80692 238
A3SS 12123 300
IR 503 21
E18 vs. P9
ES 18776 921
MXE 2938 188
A5SS 8384 241
A3SS 11645 290
IR 452 15
P0 vs. P3
ES 24298 281
MXE 4296 131
A5SS 9669 82
A3SS 13227 108
IR 586 5
P0 vs. P6
ES 23843 194
MXE 4265 33
A5SS 9581 46
A3SS 13119 88
IR 583 6
Continued
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Finally, we adopted a proteogenomics approach to identify expression of novel transcripts in mouse lens pro-
teome and subsequently validated these novel peptides through MS/MS spectra of corresponding synthetic pep-
tides. In silico analyses identified a total of 55 novel peptides in mouse lens protome. Of these, only 20 peptides 
passed a more stringent criterium i.e. ≥2 amino acids mismatches and an XCorr score ≥2.5. These 20 novel 
peptides were validated through MS/MS spectra of corresponding synthetic peptides. We are currently investi-
gating the identity of the proteins harboring these novel peptides and examining their biological significance in 
lens morphogenesis.
In conclusion, we represent a comprehensive developing mouse lens profile through the identification of novel 
transcripts, novel fuson genes, and novel AS events. Additionally, we integrate our OMIC datasets to identify 
novel peptides in developing mouse lens.
Materials and Methods
mRNA sequencing data. The Illumina paired-end mRNA sequencing data (GEO series accession number 
GSE69221) was used for the downstream bioinformatics analysis. The paired-end raw reads were processed to 
remove the adapter sequences using SeqPrep (https://github.com/jstjohn/SeqPrep). The quality of the pre-pro-
cessed reads was evaluated with FastQC (www.bioinformatics.babraham.ac.uk/projects/fastqc) and low-quality 
reads were removed prior to the downstream analysis.
Mapping and transcript annotation of mRNA sequencing data. HISAT2 (Hierarchical Indexing for 
Spliced Alignment of Transcripts), a spliced alignment tool (Ver. 2.1.0-beta) was used to map pre-processed reads 
to the mouse genome (NCBI37/mm9) with default parameter settings36. The BAM output files were generated 
for each sample and PCR duplicates were marked and removed from BAM files using Picard software (Ver. 2.8.3; 
https://github.com/broadinstitute/picard). Subsequently, StringTie algorithm (Ver. 1.3.3b) was used with default 
parameter settings to assemble RNA-Seq alignments into annotated and novel transcripts and estimate their 
respective expression level37. The expression of these transcripts was normalized using transcripts per million 
(TPM) algorithm and the number of known, and novel transcripts were estimated from the output GTF file gen-
erated by StringTie with expression threshold (≥1.0 TPM).
Identification of AS events. AS events were identified through rMATS software (Ver. 3.2.5)38. The 
mRNA-Seq alignment files (bam files) generated by the HISAT2 was used as an input for the rMATS analysis. 
The Mus musculus RefSeq gene annotations (GRcm38/mm10) was used as a reference with default parameter 
settings. Finally, the rMATS was used to calculate p-value and false discovery rate (FDR) for AS events among 
different developmental time points.
Identification of fusion genes. JAFFA (Ver. 1.08), a multi-step pipeline was used in a hybrid mode 
to detect fusion genes in mRNA sequencing data39. The Mus musculus reference genome (GRcm38/mm10), 
Developmental Stage Types of AS Events Total AS Events Significant Novel AS Events*
P0 vs. P9
ES 22985 214
MXE 4137 49
A5SS 9293 67
A3SS 12681 114
IR 533 9
P3 vs. P6
ES 20632 149
MXE 4121 108
A5SS 9142 62
A3SS 12526 89
IR 542 3
P3 vs. P9
ES 19721 143
MXE 3816 60
A5SS 8832 54
A3SS 12003 78
IR 499 4
P6 vs. P9
ES 19208 64
MXE 4083 17
A5SS 8672 46
A3SS 11934 65
IR 492 2
Table 2. Alternative splicing events identified in developing mouse lens. Note: AS: alternative splicing; ES: exon 
skipping; MXE: mutually exclusive exon; A5SS: alternative 5′ splice site; A3SS: alternative 3′ splice site; and IR: 
intron retention. *Significant events based on false discovery rate (FDR) <0.01. E15 and E18 are embryonic 
days 15, and 18, and P0, P3, P6, and P9 are postnatal days 0, 3, 6, and 9, respectively.
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transcripts annotations and sequences from mouse GENCODE Ver. M15 (GRCm38) were used as a reference for 
fusion gene identification using default JAFFA parameter settings.
Gene ontologies functional enrichment analysis. A functional annotation analysis of mouse lens 
genes was investigated using Visual Annotation Display (VLAD; Ver. 1.6.0), a web-based tool from the Mouse 
Genome Informatics (MGI)40. The VLAD tool performs the statistical analysis to test the enrichment of gene 
ontology (GO) terms based on their annotations to gene function and mammalian phenotype40. A complete set 
of mouse genes was used as a reference annotation dataset and ontological terms annotated with the evidence 
code ND (no biological data) were excluded from the enrichment analysis. The statistically significant enriched 
terms were sorted based on their corrected p-value (≤0.01) calculated using multiple testing and positive false 
discovery rate for each term.
Proteogenomic analysis of novel transcripts in lens proteome. The mRNA sequencing data was 
used to extract Fasta sequences of novel transcripts using bedtools getfasta tool (Ver. 2.25.0; http://bedtools.
readthedocs.io/en/latest/content/tools/getfasta.html) with the transcript coordinates output by StringTie. The 
novel transcripts were translated into three open reading frames (ORFs) using in-house generated Python script 
to generate a dataset of all potential proteins resulting from the translation of the novel transcripts. The theoretical 
protein dataset was screened to remove shorter proteins (<6 amino acids long) and the resulting dataset was used 
as a reference database.
The MS/MS spectra from mouse lens proteome were interrogated against the reference database (generated 
above, using the Python script) using the SEQUEST search algorithm through the Proteome Discoverer Suite 
No. Novel Peptide
Amino Acid 
Length
Number of 
PSMs Novel Transcript ID
Genomic 
Coordinates 
(mm10)
1 AAESDLSTARPAPPEPR 17 1 MSTRG.4120.3 Chr11: 117620218–117620288
2 AFAHAEPR 8 2 MSTRG.6156.3 Chr13: 120244503–120244596
3 ATEDCFQER 9 2 MSTRG.5109.18 Chr12: 113023646–113023713
4 AVGVDCSAPEPR 12 2 MSTRG.3713.5 Chr11: 97361423–97363714
5 DLGGVESASPSAAR 14 1 MSTRG.19717.4 Chr7: 137903048–137903154
6 DREIWLNR 8 4 MSTRG.12904.4 Chr2: 177493993–177494080
7 GLQRPDGGDHR 11 2 MSTRG.398.2 Chr1: 65973222–65973464
8 LCGACGTASGTK 12 3 MSTRG.16432.2 Chr5: 112688277–112688395
9 LRHLNNVNILK 11 2 MSTRG.11709.1 Chr2: 38729037–38735032
10 NYFYTGAEIK 10 1 MSTRG.19785.1 Chr7: 146523115–146545389
11 QGISSISTFK 10 3 MSTRG.18410.1 Chr7: 19857400–19857609
12 SAQALVK 7 2 MSTRG.6483.20 Chr14: 48326083–48326173
13 SINEVIK 7 1 MSTRG.5839.2 Chr13: 74088982–74089093
14 SMGEDTVPK 9 1 MSTRG.6973.3 Chr14: 121639196–121639264
15 WLIEISK 7 3 MSTRG.8658.5 Chr17: 3516990–3517538
16 FLTVSTSPGFPGT 13 1 MSTRG.16436.1 Chr5: 112684967–112698364
17 AAGDAEPEDQAQPQPQPEPEPR 22 4 MSTRG.5528.4 Chr13: 46517220–46517274
18 LGHVGGADGANPSSAGSPQDGR 22 1 MSTRG.3412.1 Chr11: 77839387–77839530
19 SPGSEPQTQEAQEAGSDPQAARPQR 25 2 MSTRG.18532.2 Chr7: 28289684–28289782
20 ERPTPDVGDGQGPQLSESSSSPFSIPPDK 29 11 MSTRG.12232.3 Chr2: 120330209–120330655
Table 3. Novel peptides identified in mouse lens through integration of OMIC (Transcriptome and Proteome) 
datasets22,24. All 20 peptides were validated through matching MS/MS spectra of synthetic peptides. Note: PSMs: 
Peptide Spectrum Matches.
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Figure 2. Validation through matching MS/MS spectra of synthetic peptides. (A) MS/MS spectra of a novel 
peptide (WLIEISK) shown with a similar fragmentation pattern observed from the corresponding synthetic 
peptide. (B) MS/MS spectra of a novel peptide (SMGEDTVPK) shown with a similar fragmentation pattern 
observed from the corresponding synthetic peptide. (C) MS/MS spectra of a novel peptide (LCGACGTASGTK) 
shown with a similar fragmentation pattern observed from the corresponding synthetic peptide. Note: the 
term “peptide identified from sample” refers to the MS/MS spectra identified in mouse lens proteome24, and 
the synthetic peptide refers to MS/MS spectra of the peptide synthesized by JPT Peptide Technologies (Berlin, 
Germany).
A. Mouse Lens Transcriptome (RNA-Seq) B. Mouse Lens Proteome (TMT)
Stage Replicates Genes Total Genes Stage TMT Proteins Total Proteins
E15 E15AE15B 13,274
14,465
E15
Set 1 4,630
5,404
E18
P0
E18 E18AE18B 13,900
P3
P6
P9
P0 P0AP0B 12,560
E15
Set 2 4,426
E18
P0
P3 P3AP3B 12,940
P3
P6
P9
P6 P6AP6B 12,130
E15
Set 3 3,747
E18
P0
P9 P9AP9B 12,229
P3
P6
P9
Table 4. Data retrieved from previously published OMIC (Transcriptome and Proteome) datasets22,24. Note: 
E15 and E18 are embryonic days 15, and 18, and P0, P3, P6, and P9 are postnatal days 0, 3, 6, and 9, respectively.
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(Ver. 2.1; Thermo Scientific, Bremen, Germany). The parameters for the Proteome Discoverer included, trypsin 
as a proteolytic enzyme with a maximum of two missed cleavages, acetylation of protein N-termini and oxidation 
of methionine as variable modifications, carbamidomethylation of cysteine as fixed modification, a minimum 
peptide length of 6 amino acids, and the mass tolerances of 10 ppm and 0.02 Da for precursor and fragment ions, 
respectively. The matched spectra or candidate peptides were filtered using the Percolator algorithm within the 
Proteome Discoverer suite using the false discovery rate (FDR < 0.01) at protein and peptide levels.
Finally, all peptides identified above (by interrogating the MS/MS spectra from mouse lens proteome against 
the reference database) were screened against the mouse nr protein database (NCBI) to identify novel peptides 
not present in the mouse nr protein database. Peptides with ≥2 amino acids mismatches (mouse nr protein data-
base) and XCorr score ≥2.5 were considered novel and retained for further analysis.
Validation of novel peptides through LC-MS/MS analysis of synthetic peptides. All synthetic 
peptides were purchased from JPT Peptide Technologies (Berlin, Germany). The synthetic peptides were pooled 
and labeled with 1-plex TMT reagents according to the manufacturer’s instructions (Thermo Fisher Scientific). 
The labeling reaction was performed for one hour at room temperature followed by quenching of the labe-
ling reaction with 100 mM Tris-HCl (pH 8.0). The labeled peptides were desalted with C18 Sep-Pak (Waters 
Corporation, Milford, MA), dried and resuspended in 0.1% formic acid. Peptides were subjected to Orbitrap 
Fusion Lumos Tribrid Mass Spectrometer coupled with the Easy-nLC 1200 nano-flow liquid chromatography 
system (Thermo Fisher Scientific) with similar parameters used for the mouse lens proteome profiling24.
References
 1. Mortazavi, A. et al. Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat. Methods 5(7), 621 (2008).
 2. Cloonan, N. et al. Stem cell transcriptome profiling via massive-scale mRNA sequencing. Nat. Methods 5(7), 613 (2008).
 3. Morin, R. et al. Profiling the HeLa S3 transcriptome using randomly primed cDNA and massively parallel short-read sequencing. 
Biotechniques 45(1), 81 (2008).
 4. Sultan, M. et al. A global view of gene activity and alternative splicing by deep sequencing of the human transcriptome. Science 
321(5891), 956 (2008).
 5. Maher, C. A. et al. Transcriptome sequencing to detect gene fusions in cancer. Nature 458(7234), 97 (2009).
 6. Wang, Z., Gerstein, M. & Snyder, M. RNA-Seq: a revolutionary tool for transcriptomics. Nat. Rev. Genet. 10(1), 57 (2009).
 7. Roberts, A. et al. Identification of novel transcripts in annotated genomes using RNA-Seq. Bioinformatics. 27(17), 2325 (2011).
 8. Xu, Q., Modrek, B. & Lee, C. Genome-wide detection of tissue-specific alternative splicing in the human transcriptome. Nucleic 
Acids Res. 30(17), 3754 (2002).
 9. Wang, E. T. et al. Alternative isoform regulation in human tissue transcriptomes. Nature 456(7221), 470 (2008).
 10. Mitelman, F., Johansson, B. & Mertens, F. The impact of translocations and gene fusions on cancer causation. Nat. Rev. Cancer 7(4), 
233 (2007).
 11. Honeyman, J. N. et al. Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma. 
Science 343(6174), 1010 (2014).
 12. Gingeras, T. R. Implications of chimaeric non-co-linear transcripts. Nature 461(7261), 206 (2009).
 13. Li, H. et al. Gene fusions and RNA trans-splicing in normal and neoplastic human cells. Cell Cycle 8(2), 218 (2009).
 14. Zhang, Y. et al. Chimeric transcript generated by cis-splicing of adjacent genes regulates prostate cancer cell proliferation. Cancer 
Discov. 2(7), 598 (2012).
 15. Qin, F. et al. Discovery of CTCF-sensitive Cis-spliced fusion RNAs between adjacent genes in human prostate cells. PLoS. Genet. 
11(2), e1005001 (2015).
 16. Croft, L. et al. ISIS, the intron information system, reveals the high frequency of alternative splicing in the human genome. Nat. 
Genet. 24(4), 340 (2000).
 17. Pan, Q. et al. Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat 
Genet. 40(12), 1413 (2008).
 18. Nilsen, T. W. & Graveley, B. R. Expansion of the eukaryotic proteome by alternative splicing. Nature 463(7280), 457 (2010).
 19. Kim, J. W. et al. NRL-Regulated Transcriptome Dynamics of Developing Rod Photoreceptors. Cell Rep. 17(9), 2460 (2016).
 20. Yasuda, M. et al. Transcriptome profiling of the rat retina after optic nerve transection. Sci. Rep. 6, 28736 (2016).
 21. Srivastava, R. et al. Transcriptome analysis of developing lens reveals abundance of novel transcripts and extensive splicing 
alterations. Sci. Rep. 7(1), 11572 (2017).
 22. Khan, S. Y. et al. Transcriptome Profiling of Developing Murine Lens Through RNA Sequencing. Invest Ophthalmol. Vis. Sci. 56(8), 
4919 (2015).
 23. Khan, S. Y., Hackett, S. F. & Riazuddin, S. A. Non-coding RNA profiling of the developing murine lens. Exp. Eye Res. 145, 347 (2016).
 24. Khan, S. Y. et al. Proteome Profiling of Developing Murine Lens Through Mass Spectrometry. Invest Ophthalmol. Vis. Sci. 59(1), 100 
(2018).
 25. Heim, S. & Mitelman, F. Molecular screening for new fusion genes in cancer. Nat. Genet. 40(6), 685 (2008).
 26. Babiceanu, M. et al. Recurrent chimeric fusion RNAs in non-cancer tissues and cells. Nucleic Acids Res. 44(6), 2859 (2016).
 27. Jia, Y., Xie, Z. & Li, H. Intergenically Spliced Chimeric RNAs in Cancer. Trends Cancer 2(9), 475 (2016).
 28. Tang, Y. et al. Recurrent fusion RNA DUS4L-BCAP29 in non-cancer human tissues and cells. Oncotarget. 8(19), 31415 (2017).
 29. Wan, J. et al. Dynamic usage of alternative splicing exons during mouse retina development. Nucleic Acids Res. 39(18), 7920 (2011).
 30. Gamsiz, E. D. et al. Genome-wide transcriptome analysis in murine neural retina using high-throughput RNA sequencing. 
Genomics. 99(1), 44 (2012).
 31. Farkas, M. H. et al. Transcriptome analyses of the human retina identify unprecedented transcript diversity and 3.5 Mb of novel 
transcribed sequence via significant alternative splicing and novel genes. BMC. Genomics. 14, 486 (2013).
 32. Li, M. et al. Comprehensive analysis of gene expression in human retina and supporting tissues. Hum. Mol. Genet. 23(15), 4001 (2014).
 33. Pinelli, M. et al. An atlas of gene expression and gene co-regulation in the human retina. Nucleic Acids Res. 44(12), 5773 (2016).
 34. Zelinger, L. & Swaroop, A. RNA Biology in Retinal Development and Disease. Trends Genet (2018).
 35. Akin, D. et al. RNA-seq analysis of impact of PNN on gene expression and alternative splicing in corneal epithelial cells. Mol. Vis. 
22, 40 (2016).
 36. Kim, D., Langmead, B. & Salzberg, S. L. HISAT: a fast spliced aligner with low memory requirements. Nat Methods 12(4), 357 (2015).
 37. Pertea, M. et al. StringTie enables improved reconstruction of a transcriptome from RNA-seq reads. Nat Biotechnol. 33(3), 290 
(2015).
 38. Shen, S. et al. rMATS: robust and flexible detection of differential alternative splicing from replicate RNA-Seq data. Proc. Natl. Acad. 
Sci. USA 111(51), E5593–E5601 (2014).
www.nature.com/scientificreports/
9Scientific RepoRts |  (2018) 8:11162  | DOI:10.1038/s41598-018-28727-w
 39. Davidson, N. M., Majewski, I. J. & Oshlack, A. JAFFA: High sensitivity transcriptome-focused fusion gene detection. Genome Med. 
7(1), 43 (2015).
 40. Richardson, J. E. & Bult, C. J. Visual annotation display (VLAD): a tool for finding functional themes in lists of genes. Mamm. 
Genome 26(9-10), 567 (2015).
Acknowledgements
The work was supported by National Eye Institute Grant R01EY022714 (SAR).
Author Contributions
S.Y.K., C.H.N. and S.A.R.: conceived and designed the experiments; C.H.N. and N.P. and S.A.R.: contributed 
reagents, materials, and analytical tools; S.Y.K., M.A., F.K., R.C., C.H.N., S.F.H. and S.A.R.: performed 
experiments; S.Y.K., R.C., C.H.N., M.C.W.L. and S.A.R.: analyzed the data; S.Y.K., M.A., F.K., R.C., C.H.N., 
M.C.W.L., N.P., S.F.H. and S.A.R.: contributed to writing the manuscript.
Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-28727-w.
Competing Interests: The authors declare no competing interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2018
